Stock LUCD LUCID DIAGNOSTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-01 EDT 		5-day change 1st Jan Change
0.8787 USD -2.48% Intraday chart for Lucid Diagnostics Inc. +28.63% -37.68%
03-27 Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating MT
03-26 Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Lucid Diagnostics Inc. Announces Positive Data from the First Prospective Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population
Lucid Diagnostics Inc. Executes Contract to Provide Esoguard® Esophageal Precancer Testing as A Covered Benefit for 9/11 Responders and Survivors
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lucid Diagnostics Inc. Appoints Shaun M. O?Neil as President
Lucid Diagnostics Inc. Releases Positive Data from First Prospective Clinical Utility Study of Esoguard®? Esophageal Precancer Detection
Lucid Diagnostics Inc. Releases Positive Data Demonstrating Clinical Utility of EsoGuard®? Esophageal Precancer Detection in Fire Fighters
Lucid Diagnostics to Provide Esophageal Pre-Cancer Screening to Ancira Auto Employees
Lucid Diagnostics Inc. Executes First Direct Employer Contract to Provide EsoGuard®? Esophageal Precancer Testing as an Employee Benefit
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Lucid Diagnostics Launches First Esoguard® Mobile Test Unit
Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Lucid Diagnostics Inc. Announces Findings from Two Clinical Studies of its EsoGuard®? Esophageal DNA Test and EsoCheck®? Cell Collection Device
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Elon Musk's challenge: Stay ahead of the competition
PAVmed, Subsidiaries to Cut 20% of Jobs, Streamline Product Portfolio to Reduce Quarterly Cash Burn
Sector Update: Health Care Stocks Fading in Late Tuesday Trading
Sector Update: Health Care
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LUCD Stock
  4. News Lucid Diagnostics Inc.
  5. Other languages